Investor Relations

Latest Financial Results

Q3 2023

Quarter Ended September 30, 2023
Financial Results

Latest Annual Filing

For Fiscal Year Ending September 30, 2022

Company Overview

NeuBase is accelerating the genetic revolution by developing a new class of precision genetic medicines which can be designed to increase, decrease, or change gene function, as appropriate, to resolve genetic defects that drive disease. NeuBase’s targeted PATrOL™ therapies are centered around its proprietary drug scaffold to address genetic diseases at the DNA or RNA level by combining the highly targeted approach of traditional genetic therapies with the broad organ distribution capabilities of small molecules. With an initial focus on silencing disease-causing mutations in debilitating neuromuscular, neurological and oncologic disorders, NeuBase is committed to redefining medicine for the millions of patients with both common and rare conditions.

IR Contacts


NeuBase Therapeutics, Inc.
350 Technology Drive
Pittsburgh, PA 15219
T: 412-763-3350

Transfer Agent

Standard Registrar and Transfer Company
440 East 400 South
Suite 200
Salt Lake City, UT 84111
T: 801-571-8844